Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

doi:10.1038/nature11519

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Nature - 18 Oct 2012

Rolland Morgane, Edlefsen Paul T, Larsen Brendan B, Tovanabutra Sodsai, Sanders-Buell Eric, Hertz Tomer, deCamp Allan C, Carrico Chris, Menis Sergey, Magaret Craig A, Ahmed Hasan, Juraska Michal, Chen Lennie, Konopa Philip, Nariya Snehal, Stoddard Julia N, Wong Kim, Zhao Hong, Deng Wenjie, Maust Brandon S, Bose Meera, Howell Shana, Bates Adam, Lazzaro Michelle, O'Sullivan Annemarie, Lei Esther, Bradfield Andrea, Ibitamuno Grace, Assawadarachai Vatcharain, O'Connell Robert J, deSouza Mark S, Nitayaphan Sorachai, Rerks-Ngarm Supachai, Robb Merlin L, McLellan Jason S, Georgiev Ivelin, Kwong Peter D, Carlson Jonathan M, Michael Nelson L, Schief William R, Gilbert Peter B, Mullins James I, Kim Jerome H

Abstract excerpt

The RV144 trial demonstrated 31% vaccine efficacy at preventing human immunodeficiency virus (HIV)-1 infection. Antibodies against the HIV-1 envelope variable loops 1 and 2 (Env V1 and V2) correlated inversely with infection risk. We proposed that vaccine-induced immune responses against V1/V2 would have a selective effect against, or sieve, HIV-1 breakthrough viruses. A total of 936 HIV-1 genome sequences from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to AIDS Vaccines

Share to env Gene Products, Human Immunodeficiency Virus

Share to HIV-1

Share to HIV Antibodies

Share to HIV Infections

Share to Phylogeny

Share to Randomized Controlled Trials as Topic

Share to Sequence Analysis, DNA

Source

Open in PubMed Open full text

Identifiers

PMID: 22960785
DOI: 10.1038/nature11519
PMCID: PMC3551291

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.PMID 22960785Read ↗

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.Semantic proximity Read ↗

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.Semantic proximity Read ↗

Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved.Semantic proximity Read ↗

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee.Semantic proximity Read ↗

V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC ActivitySemantic proximity Read ↗

The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta BarrelSemantic proximity Read ↗

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.Semantic proximity Read ↗

FCGR2C Polymorphisms Associated with HIV-1 Vaccine Protection Are Linked to Altered Gene Expression of Fc-γ Receptors in Human B Cells.Semantic proximity Read ↗

The changing face of HIV vaccine research.Semantic proximity Read ↗

Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIVSemantic proximity Read ↗

Sieve analysis in HIV-1 vaccine efficacy trials.Semantic proximity Read ↗

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.